David Hogg
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David Hogg has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Anna Spreafico
Division of Medical Oncology, the Princess Margaret Cancer Centre/University of Toronto, Canada
3 shared publications - Marcus Otho Butler
Princess Margaret Cancer Centre 2 Division of Medical Oncology and Hematology , Toronto, Canada
3 shared publications - Diana Gray
Department of Medicine, Division of Medical Oncology, University of Toronto, Toronto, Ontario, Canada
2 shared publications - Natasha B. Leighl
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
2 shared publications - Thiago Pimentel Muniz
Princess Margaret Cancer Center, Division of Medical Oncology and Hematology, Department of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada
2 shared publications - Yada Kanjanapan
Australian National University & Canberra Hospital
2 shared publications
Latest Publications
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , e21575
Real-world changes in the clinical management of resected stage III melanoma at high risk of local recurrence in the era of modern systemic therapies.
E21575 Background: Adjuvant systemic therapies (ST) for patients with resected stage III melanoma have improved relapse-free survival; however, the role of adjuvant radiotherapy (RT), previously the mainstay adjuvant treatment, is undefined in the modern ST era. Real-world data detailing clinical practice changes and its impact on outcomes are needed to help inform the choice of adjuvant therapy for patients with resected stage III melanoma. Methods: In this single-center retrospective study, patients from Princess Margaret Cancer Centre with resected stage III cutaneous melanoma treated between 2010 and 2019 and fitting the 2016 Cancer Care Ontario guidelines for adjuvant RT were included. Demographic, pathological, and clinical data were abstracted from electronic medical records. PFS was defined as the time from lymph node dissection to local-regional recurrence in the treated nodal basin or distant recurrence. OS was defined as time from lymph node dissection to death by any cause. The Log-rank method was applied to assess survival endpoints. A p-value < 0.05 was considered statistically significant. Results: From 4,959 records reviewed, 109 patients were identified. Median age at time of surgical resection was 59.4 years (23.6-89.8), and 74 (68%) were male. Type of adjuvant therapy and number of local-regional recurrences (LR) are expressed in the table. The median follow-up among those alive at last follow-up was 54.2 months (range 1.9-122). The proportion of patients receiving adjuvant RT was higher between 2010 and 2014 than it was between 2015 and 2019 (59% to 26%), whilst the proportion of those receiving adjuvant ST progressively grew (3% to 50%). LR > 90 days following lymph node dissection as the first site of relapse or synchronously with progression to metastatic disease was rare in patients treated with either adjuvant RT (6.8%) or adjuvant ST (14.3%, chi-square p = 0.33). Median progression free survival was 12.3 months in patients treated with adjuvant RT and 43.8 months in patients treated with adjuvant ST (p = 0.007). Overall survival was not significantly different (p = 0.08). Conclusions: The advent of ST has changed our institution’s clinical practice with ST replacing RT as the primary adjuvant treatment modality. Our data suggests that in the current adjuvant treatment landscape, omission of RT does not seem to increase rates of local-regional recurrences, and patients with resected stage III melanoma can be safely spared from adjuvant RT without detrimental effect on survival.
- 1 June 2022
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 40 (16_suppl) , e21575
Real-world changes in the clinical management of resected stage III melanoma at high risk of local recurrence in the era of modern systemic therapies.
E21575 Background: Adjuvant systemic therapies (ST) for patients with resected stage III melanoma have improved relapse-free survival; however, the role of adjuvant radiotherapy (RT), previously the mainstay adjuvant treatment, is undefined in the modern ST era. Real-world data detailing clinical practice changes and its impact on outcomes are needed to help inform the choice of adjuvant therapy for patients with resected stage III melanoma. Methods: In this single-center retrospective study, patients from Princess Margaret Cancer Centre with resected stage III cutaneous melanoma treated between 2010 and 2019 and fitting the 2016 Cancer Care Ontario guidelines for adjuvant RT were included. Demographic, pathological, and clinical data were abstracted from electronic medical records. PFS was defined as the time from lymph node dissection to local-regional recurrence in the treated nodal basin or distant recurrence. OS was defined as time from lymph node dissection to death by any cause. The Log-rank method was applied to assess survival endpoints. A p-value < 0.05 was considered statistically significant. Results: From 4,959 records reviewed, 109 patients were identified. Median age at time of surgical resection was 59.4 years (23.6-89.8), and 74 (68%) were male. Type of adjuvant therapy and number of local-regional recurrences (LR) are expressed in the table. The median follow-up among those alive at last follow-up was 54.2 months (range 1.9-122). The proportion of patients receiving adjuvant RT was higher between 2010 and 2014 than it was between 2015 and 2019 (59% to 26%), whilst the proportion of those receiving adjuvant ST progressively grew (3% to 50%). LR > 90 days following lymph node dissection as the first site of relapse or synchronously with progression to metastatic disease was rare in patients treated with either adjuvant RT (6.8%) or adjuvant ST (14.3%, chi-square p = 0.33). Median progression free survival was 12.3 months in patients treated with adjuvant RT and 43.8 months in patients treated with adjuvant ST (p = 0.007). Overall survival was not significantly different (p = 0.08). Conclusions: The advent of ST has changed our institution’s clinical practice with ST replacing RT as the primary adjuvant treatment modality. Our data suggests that in the current adjuvant treatment landscape, omission of RT does not seem to increase rates of local-regional recurrences, and patients with resected stage III melanoma can be safely spared from adjuvant RT without detrimental effect on survival.
- 1 October 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (10) , 2470-2479
Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor‒Like Melanoma
- 1 October 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (10) , 2470-2479
Genomic Landscape of Malignant Peripheral Nerve Sheath Tumor‒Like Melanoma
- 10 March 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (8_suppl) , 85
Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy.
85 Background: Prior clinical trials in melanoma have demonstrated higher rates of irAEs from combination ICI therapy compared to monotherapy. However, this has not been well studied in the real-world where patients often have greater co-morbidities and less organ reserve. We aim to compare irAEs hospitalizations for melanoma patients on combination vs monotherapy ICIs. Methods: We performed a single centre retrospective chart review (Princess Margaret Cancer Centre, Toronto, ON) for all melanoma patients receiving ICI as standard of care (2012-2017) admitted with irAEs. Data collected include demographics, investigations, management and outcomes of hospitalizations. Descriptive analyses were performed to characterize hospitalizations and compare between ICI combination vs monotherapy groups. Results: Among 381 melanoma patients identified on standard of care ICI, 41 (11%) were admitted for irAE. Among those admitted, 10% received monotherapy with nivolumab, 22% pembrolizumab, 39% ipilimumab and 29% combination ICI. Admission rates were higher among patients receiving combination ICI compared to monotherapy (20% vs 8% p = 0.003). Prevalence of the most common irAEs were similar between combination and monotherapy groups: colitis (58% vs 59%), pneumonitis (8% vs 14%) and hepatitis (8% vs 10%). Less than half received invasive diagnostic tests (i.e, endoscopy) (42% combination vs 35% monotherapy, p = 0.50) with 3 (60%) and 5 (50%) confirming irAEs, respectively. Rates of infliximab use were similar between the combination and monotherapy group (25% vs 21%, p = 0.70). Average length of stay was shorter for patients on combination ICI compared to monotherapy (5 days vs 15 days, p = 0.08). irAE readmission rates were similar between patients receiving combination ICI compared to monotherapy (20% vs 17%, p = 0.65). Conclusions: Despite higher admission rates among patients receiving combination ICI, there was a trend towards shorter hospitalizations. Other outcomes including diagnoses, investigations and management were not significantly different between patients receiving combination vs ICI monotherapy.
- 10 March 2019
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (8_suppl) , 85
Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy.
85 Background: Prior clinical trials in melanoma have demonstrated higher rates of irAEs from combination ICI therapy compared to monotherapy. However, this has not been well studied in the real-world where patients often have greater co-morbidities and less organ reserve. We aim to compare irAEs hospitalizations for melanoma patients on combination vs monotherapy ICIs. Methods: We performed a single centre retrospective chart review (Princess Margaret Cancer Centre, Toronto, ON) for all melanoma patients receiving ICI as standard of care (2012-2017) admitted with irAEs. Data collected include demographics, investigations, management and outcomes of hospitalizations. Descriptive analyses were performed to characterize hospitalizations and compare between ICI combination vs monotherapy groups. Results: Among 381 melanoma patients identified on standard of care ICI, 41 (11%) were admitted for irAE. Among those admitted, 10% received monotherapy with nivolumab, 22% pembrolizumab, 39% ipilimumab and 29% combination ICI. Admission rates were higher among patients receiving combination ICI compared to monotherapy (20% vs 8% p = 0.003). Prevalence of the most common irAEs were similar between combination and monotherapy groups: colitis (58% vs 59%), pneumonitis (8% vs 14%) and hepatitis (8% vs 10%). Less than half received invasive diagnostic tests (i.e, endoscopy) (42% combination vs 35% monotherapy, p = 0.50) with 3 (60%) and 5 (50%) confirming irAEs, respectively. Rates of infliximab use were similar between the combination and monotherapy group (25% vs 21%, p = 0.70). Average length of stay was shorter for patients on combination ICI compared to monotherapy (5 days vs 15 days, p = 0.08). irAE readmission rates were similar between patients receiving combination ICI compared to monotherapy (20% vs 17%, p = 0.65). Conclusions: Despite higher admission rates among patients receiving combination ICI, there was a trend towards shorter hospitalizations. Other outcomes including diagnoses, investigations and management were not significantly different between patients receiving combination vs ICI monotherapy.
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 3063
Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.
3063Background: A subset of patients (pts) treated with immune checkpoint inhibitors experience an accelerated tumor growth rate (TGR) compared with pre-treatment kinetics, known as hyperprogression. The aim of this study was to explore the relationship between HPD, treatment-related toxicity and clinical factors. Methods: Consecutive pts enrolled in early-phase trials involving checkpoint inhibitors and/or costimulatory molecules at Princess Margaret Cancer Centre between 8/2012 – 9/2016 with CT scans available for RECIST 1.1 assessment in the pre-IO treatment (reference, REF) and post-IO treatment (experimental, EXP) periods were reviewed. HPD was defined as RECIST progression at the first on-treatment scan and ≥2-fold increase in TGR between EXP and REF periods. Pts who had prior IO were excluded. Treatment-related toxicities requiring systemic corticosteroids, hormone replacement, IO delay or cessation were considered clinically significant adverse events (CSAEs). Results: 182/352 pts were eligible fo...
- 20 May 2018
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 36 (15_suppl) , 3063
Hyperprogressive disease (HPD) in early-phase immunotherapy (IO) trials.
3063Background: A subset of patients (pts) treated with immune checkpoint inhibitors experience an accelerated tumor growth rate (TGR) compared with pre-treatment kinetics, known as hyperprogression. The aim of this study was to explore the relationship between HPD, treatment-related toxicity and clinical factors. Methods: Consecutive pts enrolled in early-phase trials involving checkpoint inhibitors and/or costimulatory molecules at Princess Margaret Cancer Centre between 8/2012 – 9/2016 with CT scans available for RECIST 1.1 assessment in the pre-IO treatment (reference, REF) and post-IO treatment (experimental, EXP) periods were reviewed. HPD was defined as RECIST progression at the first on-treatment scan and ≥2-fold increase in TGR between EXP and REF periods. Pts who had prior IO were excluded. Treatment-related toxicities requiring systemic corticosteroids, hormone replacement, IO delay or cessation were considered clinically significant adverse events (CSAEs). Results: 182/352 pts were eligible fo...
- 7 February 2018
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 30 (4) , e12579
A novel role of the corticotrophin‐releasing hormone regulating peptide, teneurin C‐terminal associated peptide 1, on glucose uptake into the brain
Teneurin C‐terminal associated peptide (TCAP) is an ancient paracrine signalling agent that evolved via lateral gene transfer from prokaryotes into an early metazoan ancestor. Although it bears structural similarity to corticotrophin‐releasing hormone (CRH), it inhibits the in vivo actions of CRH. The TCAPs are highly expressed in neurones, where they induce rapid cytoskeletal rearrangement and are neuroprotective. Because these processes are highly energy‐dependent, this suggests that TCAP has the potential to regulate glucose uptake because glucose is the primary energy substrate in brain, and neurones require a steady supply to meet the high metabolic demands of neuronal communication. Therefore, the objective of the present study was to assess the effect of TCAP‐mediated glucose uptake in the brain and in neuronal cell models. TCAP‐mediated 18F‐deoxyglucose (FDG) uptake into brain tissue was assessed in male wild‐type Wistar rats by functional positron emission tomography. TCAP‐1 increased FDG uptake by over 40% into cortical regions of the brain, demonstrating that TCAP‐1 can significantly enhance glucose supply. Importantly, a single nanomolar injection of TCAP‐1 increased brain glucose after 3 days and decreased blood glucose after 1 week. This is corroborated by a decreased serum concentration of insulin and an increased serum concentration of glucagon. In immortalised hypothalamic neurones, TCAP‐1 increased ATP production and enhanced glucose uptake by increasing glucose transporter recruitment to the plasma membrane likely via AKT and mitogen‐activated protein kinase/ERK phosphorylation events. Taken together, these data demonstrate that TCAP‐1 increases glucose metabolism in neurones, and may represent a peptide signalling agent that regulated glucose uptake before insulin and related peptides.
- 7 February 2018
- Published by Wiley in Journal of Neuroendocrinology
- Vol. 30 (4) , e12579
A novel role of the corticotrophin‐releasing hormone regulating peptide, teneurin C‐terminal associated peptide 1, on glucose uptake into the brain
Teneurin C‐terminal associated peptide (TCAP) is an ancient paracrine signalling agent that evolved via lateral gene transfer from prokaryotes into an early metazoan ancestor. Although it bears structural similarity to corticotrophin‐releasing hormone (CRH), it inhibits the in vivo actions of CRH. The TCAPs are highly expressed in neurones, where they induce rapid cytoskeletal rearrangement and are neuroprotective. Because these processes are highly energy‐dependent, this suggests that TCAP has the potential to regulate glucose uptake because glucose is the primary energy substrate in brain, and neurones require a steady supply to meet the high metabolic demands of neuronal communication. Therefore, the objective of the present study was to assess the effect of TCAP‐mediated glucose uptake in the brain and in neuronal cell models. TCAP‐mediated 18F‐deoxyglucose (FDG) uptake into brain tissue was assessed in male wild‐type Wistar rats by functional positron emission tomography. TCAP‐1 increased FDG uptake by over 40% into cortical regions of the brain, demonstrating that TCAP‐1 can significantly enhance glucose supply. Importantly, a single nanomolar injection of TCAP‐1 increased brain glucose after 3 days and decreased blood glucose after 1 week. This is corroborated by a decreased serum concentration of insulin and an increased serum concentration of glucagon. In immortalised hypothalamic neurones, TCAP‐1 increased ATP production and enhanced glucose uptake by increasing glucose transporter recruitment to the plasma membrane likely via AKT and mitogen‐activated protein kinase/ERK phosphorylation events. Taken together, these data demonstrate that TCAP‐1 increases glucose metabolism in neurones, and may represent a peptide signalling agent that regulated glucose uptake before insulin and related peptides.
- 13 April 2015
- Published by Wiley in The Journal of Physiology
- Vol. 593 (10) , 2311-2326
Decreases in mitochondrial reactive oxygen species initiate GABAA receptor‐mediated electrical suppression in anoxia‐tolerant turtle neurons
Key points: Anoxia induces hyper‐excitability and cell death in mammalian brain but in the western painted turtle (Chrysemys picta bellii) enhanced GABA transmission prevents injury. The mechanism responsible for increased GABA transmission is unknown; however, reactive oxygen species (ROS) generated by mitochondria may play a role because this is an oxygen‐sensitive process. In this study, we show that inhibition of mitochondrial ROS production is sufficient to initiate a redox‐sensitive GABA signalling cascade that suppresses pyramidal neuron action potential frequency. These results further our understanding of the turtle's unique strategy for reducing ATP consumption during anoxia and highlights a natural mechanism in which to explore therapies to protect mammalian brain from low‐oxygen insults (e.g. cerebral stroke). Anoxia induces hyper‐excitability and cell death in mammalian brain but in the anoxia‐tolerant western painted turtle (Chrysemys picta bellii) neuronal electrical activity is suppressed (i.e. spike arrest), adenosine triphosphate (ATP) consumption is reduced, and cell death does not occur. Electrical suppression is primarily the result of enhanced γ‐aminobutyric acid (GABA) transmission; however, the underlying mechanism responsible for initiating oxygen‐sensitive GABAergic spike arrest is unknown. In turtle cortical pyramidal neurons there are three types of GABAA receptor‐mediated currents: spontaneous inhibitory postsynaptic currents (IPSCs), giant IPSCs and tonic currents. The aim of this study was to assess the effects of reactive oxygen species (ROS) scavenging on these three currents since ROS levels naturally decrease with anoxia and may serve as a redox signal to initiate spike arrest. We found that anoxia, pharmacological ROS scavenging, or inhibition of mitochondrial ROS generation enhanced all three types of GABA currents, with tonic currents comprising ∼50% of the total current. Application of hydrogen peroxide inhibited all three GABA currents, demonstrating a reversible redox‐sensitive signalling mechanism. We conclude that anoxia‐mediated decreases in mitochondrial ROS production are sufficient to initiate a redox‐sensitive inhibitory GABA signalling cascade that suppresses electrical activity when oxygen is limited. This unique strategy for reducing neuronal ATP consumption during anoxia represents a natural mechanism in which to explore therapies to protect mammalian brain from low‐oxygen insults.
- 13 April 2015
- Published by Wiley in The Journal of Physiology
- Vol. 593 (10) , 2311-2326
Decreases in mitochondrial reactive oxygen species initiate GABAA receptor‐mediated electrical suppression in anoxia‐tolerant turtle neurons
Key points: Anoxia induces hyper‐excitability and cell death in mammalian brain but in the western painted turtle (Chrysemys picta bellii) enhanced GABA transmission prevents injury. The mechanism responsible for increased GABA transmission is unknown; however, reactive oxygen species (ROS) generated by mitochondria may play a role because this is an oxygen‐sensitive process. In this study, we show that inhibition of mitochondrial ROS production is sufficient to initiate a redox‐sensitive GABA signalling cascade that suppresses pyramidal neuron action potential frequency. These results further our understanding of the turtle's unique strategy for reducing ATP consumption during anoxia and highlights a natural mechanism in which to explore therapies to protect mammalian brain from low‐oxygen insults (e.g. cerebral stroke). Anoxia induces hyper‐excitability and cell death in mammalian brain but in the anoxia‐tolerant western painted turtle (Chrysemys picta bellii) neuronal electrical activity is suppressed (i.e. spike arrest), adenosine triphosphate (ATP) consumption is reduced, and cell death does not occur. Electrical suppression is primarily the result of enhanced γ‐aminobutyric acid (GABA) transmission; however, the underlying mechanism responsible for initiating oxygen‐sensitive GABAergic spike arrest is unknown. In turtle cortical pyramidal neurons there are three types of GABAA receptor‐mediated currents: spontaneous inhibitory postsynaptic currents (IPSCs), giant IPSCs and tonic currents. The aim of this study was to assess the effects of reactive oxygen species (ROS) scavenging on these three currents since ROS levels naturally decrease with anoxia and may serve as a redox signal to initiate spike arrest. We found that anoxia, pharmacological ROS scavenging, or inhibition of mitochondrial ROS generation enhanced all three types of GABA currents, with tonic currents comprising ∼50% of the total current. Application of hydrogen peroxide inhibited all three GABA currents, demonstrating a reversible redox‐sensitive signalling mechanism. We conclude that anoxia‐mediated decreases in mitochondrial ROS production are sufficient to initiate a redox‐sensitive inhibitory GABA signalling cascade that suppresses electrical activity when oxygen is limited. This unique strategy for reducing neuronal ATP consumption during anoxia represents a natural mechanism in which to explore therapies to protect mammalian brain from low‐oxygen insults.
- 1 August 2013
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 48 (4) , e74-e76
Bilateral extraocular muscles metastases from a choroidal melanoma
- 1 August 2013
- Published by Elsevier in Canadian Journal of Ophthalmology
- Vol. 48 (4) , e74-e76
Bilateral extraocular muscles metastases from a choroidal melanoma